Oxford Textbook of Rheumatoid Arthritis
Herausgeber: Scott, David L; Strand, Vibeke; Pratt, Arthur; Cope, Andrew; Galloway, James
Oxford Textbook of Rheumatoid Arthritis
Herausgeber: Scott, David L; Strand, Vibeke; Pratt, Arthur; Cope, Andrew; Galloway, James
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
The Oxford Textbook of Rheumatoid Arthritis covers all relevant aspects of the fisease, ranging from basic science, epidemiology, clinical and laboratory assessments, drug and non-drug treatments, and disease outcomes. Written by an international team of experts, it will be an invaluable resource for those involved with people with RA.
Andere Kunden interessierten sich auch für
- A Clinical Guide to Rheumatoid Arthritis160,99 €
- Oxford Textbook of Rheumatology770,99 €
- Oxford Textbook of Sjögren's Syndrome228,99 €
- Oxford Textbook of Axial Spondyloarthritis260,99 €
- Oxford Textbook of Psoriatic Arthritis189,99 €
- Understanding Rheumatoid Arthritis158,99 €
- Mark DuttonDutton's Orthopedic Survival Guide: Managing Common Conditions110,99 €
-
-
-
The Oxford Textbook of Rheumatoid Arthritis covers all relevant aspects of the fisease, ranging from basic science, epidemiology, clinical and laboratory assessments, drug and non-drug treatments, and disease outcomes. Written by an international team of experts, it will be an invaluable resource for those involved with people with RA.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Oxford University Press
- Seitenzahl: 576
- Erscheinungstermin: 17. November 2020
- Englisch
- Abmessung: 279mm x 211mm x 28mm
- Gewicht: 1637g
- ISBN-13: 9780198831433
- ISBN-10: 0198831439
- Artikelnr.: 58462013
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- 06621 890
- Verlag: Oxford University Press
- Seitenzahl: 576
- Erscheinungstermin: 17. November 2020
- Englisch
- Abmessung: 279mm x 211mm x 28mm
- Gewicht: 1637g
- ISBN-13: 9780198831433
- ISBN-10: 0198831439
- Artikelnr.: 58462013
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- 06621 890
David L. Scott is Professor of Clinical Rheumatology at King's College London. He trained in medicine and rheumatology in Leeds and Birmingham and subsequently held a fellowship at St Bartholomew's Hospital in London. His current academic focus spans the outcomes of rheumatoid arthritis and the impact of intensive treatment in improving outcomes in clinical trials. James Galloway is Senior Lecturer in Rheumatology at King's College London and Honorary Consultant Rheumatologist at King's College Hospital. After training in medicine and rheumatology in Bristol and Manchester he held a fellowship at the Arthritis Research UK Epidemiology Unit in Manchester. His current academic focus is on large observational studies of arthritis and treatment risks including infections Andrew Cope is Arthritis Research UK Professor of Rheumatology at King's College London and Honorary Consultant Rheumatologist at Guy's and St Thomas's Hospital. After training in medicine and rheumatology in London he held fellowships at the Kennedy Institute of Rheumatology and Stanford University. His current academic focus spans laboratory studies, clinical trials and observational studies with an emphasis on understanding the immunobiology of inflammatory arthritis. Arthur Pratt is Clinical Fellow in the Institute of Cellular Medicine and Honorary Consultant Rheumatologist at the Freeman Hospital in Newcastle. He trained in medicine and rheumatology in Leeds and Newcastle. Subsequently he was a training fellow and National Institute for Health Clinical Lecturer at Newcastle University. His current academic focus is clinical and laboratory assessments and predictors in early inflammatory arthritis. Vibeke Strand is Adjunct Clinical Professor, in the Division of Immunology and Rheumatology at Stanford University. She is a clinical rheumatologist and acts as a consultant in biopharmaceutics, clinical research, and regulatory affairs to many pharmaceutical and biotech companies. After graduating from Swarthmore College she trained in medicine and rheumatology at University of California San Francisco School of Medicine. Her current academic focus spans clinical trial design, development of outcome measures with an emphasis on patient reported outcomes and regulatory strategies leading to approval of new agents for treatment of autoimmune diseases. She gives particular emphasis to translating basic research findings into rationally designed clinical trials, evaluating their results and helping patients access new treatments.
* 1. History, diagnosis, and epidemiology
* 1: David L. Scott: The history of rheumatoid arthritis
* 2: Daniel Aletaha and Helga Radner: Diagnosis
* 3: James Gwinnutt and Deborah Symmons: The descriptive epidemiology
of rheumatoid arthritis
* 4: Lars Klareskog and Lars Alfredsson: Modifiable and other risk
factors for rheumatoid arthritis: a basis for prevention and better
therapy
* 2. Pathogenesis
* 5: Anne Barton: Genetics and epigenetics of rheumatoid arthritis
* 6: Thomas Crowley, Jason Turner, Andrew Filer, Andy Clark, and Chris
Buckley: Dysregulation of synovial fibroblasts in rheumatoid
arthritis
* 7: Tom W. J. Huizinga: Autoantibodies in rheumatoid arthritis
* 8: Soi-Cheng Law, Pascale Wehr, Harriet Purvis, and Ranjeny Thomas:
Dendritic cells and T cells in rheumatoid arthritis
* 9: Ukrike Steffen and Georg Schett: Mechanisms of bone and cartilage
destruction
* 10: Marina Frleta-Gilchrist and Iain B. McInnes: Cytokines and other
mediators
* 3. Clinical presentation
* 11: Annette van der Helm-van Mil: Clinical features of rheumatoid
arthritis
* 12: Karim Raza, Catherine McGrath, Laurette van Boheemen, and Dirkjan
van Schaardenburg: Pre-rheumatoid arthritis
* 13: Katherine MacDonald, Jennifer Hannah, and James Galloway:
Non-articular manifestations of rheumatoid arthritis
* 14: Kimme Hyrich and Sarah Skeoch: Comorbidity in rheumatoid
arthritis
* 4. Disease assessment
* 15: Josef Smolen: Disease activity assessment in rheumatoid arthritis
* 16: Douglas Veale and Ursula Fearon: Synovial biopsies
* 17: Charles Peterfy, Philip Conaghan, and Mikkel Østergaard:
Radiography in rheumatoid arthritis
* 18: Andrew Filer, Maria Antonietta D'Agostino, and Ilfita Sahbudin:
Ultrasound in rheumatoid arthritis
* 19: Charles Peterfy, Philip Conaghan, and Mikkel Østergaard: MRI in
rheumatoid arthritis
* 5. Impact on life
* 20: Kathryn A. Gibson and Theodore Pincus: Patient physical function
in rheumatoid arthritis
* 21: Emma Dures and Neil Basu: Fatigue
* 22: David L. Scott and Allan Wailoo: Health economics
* 23: Suzanne Verstappen, Cheryl Jones, Abdullah Houssien, and James
Galloway: Rheumatoid arthritis and work
* 6. Non-drug treatments
* 24: Lindsay Bearne and Christina Opava: Exercise
* 25: Heidi Siddle and Anthony Redmond: Foot health
* 26: Alison Hammond, Joanne Adams, and Yeliz Prior: Occupational
therapy
* 27: Marieke M.J.H. Voshaar: Self-management: a patient's perspective
* 7. Drug treatments
* 28: Mark D Russell and Nidhi Sofat: Analgesics, Opioids, and NSAIDs
* 29: Johannes W. G. Jacobs, Marlies C. van der Goes, Johannes W. J.
Bijlsma, and José A. P. da Silva: Glucocorticoids
* 30: David L. Scott: Conventional disease modifying drugs
* 31: Peter Taylor and Nehal Narayan: Tumour necrosis factor inhibitors
* 32: Neelam Hassan and Ernest Choy: Interleukin-6 inhibitors
* 33: Yuzaiful Yusof, Edward Vital, and Maya Buch: B-cell therapies
* 34: Vibeke Strand, Jeffrey Kaine, and John Isaacs: Biosimilars
* 35: Meghna Jani, John Isaacs, and Vibeke Strand: Immunogenicity in
response to biologic agents
* 36: Katie Bechman, James Galloway, and Peter Taylor: The use of JAK
inhibitors in the treatment of rheumatoid arthritis
* 37: Ben G.T. Coumbe, Elena Nikiphorou, and Tuulikki Sokka-Isler:
Combination therapy in rheumatoid arthritis
* 38: Jeremy Sokolove: Translation of new therapies: from bench to
bedside
* 39: James Galloway and Mark Yates: Adverse events in clinical studies
in rheumatoid arthritis
* 8. Management and outcomes
* 40: Tom W. J. Huizinga, Annette van der Helm-van Mil, and Andrew
Cope: Prevention of rheumatoid arthritis
* 41: Kenneth F Baker and Arthur G Pratt: Treatment targets and
remission
* 42: David L. Scott: Clinical outcomes
* 43: Anna-Birgitte Aga, Espen A. Haavardsholm, Till Uhlig, and Tore K.
Kvien: Clinical guidelines
* 44: Angela Zink and Anja Strangfeld: European biologics registers
* 45: Jeff Greenberg and Sheetal Patel: Voluntary patient registries
* 1: David L. Scott: The history of rheumatoid arthritis
* 2: Daniel Aletaha and Helga Radner: Diagnosis
* 3: James Gwinnutt and Deborah Symmons: The descriptive epidemiology
of rheumatoid arthritis
* 4: Lars Klareskog and Lars Alfredsson: Modifiable and other risk
factors for rheumatoid arthritis: a basis for prevention and better
therapy
* 2. Pathogenesis
* 5: Anne Barton: Genetics and epigenetics of rheumatoid arthritis
* 6: Thomas Crowley, Jason Turner, Andrew Filer, Andy Clark, and Chris
Buckley: Dysregulation of synovial fibroblasts in rheumatoid
arthritis
* 7: Tom W. J. Huizinga: Autoantibodies in rheumatoid arthritis
* 8: Soi-Cheng Law, Pascale Wehr, Harriet Purvis, and Ranjeny Thomas:
Dendritic cells and T cells in rheumatoid arthritis
* 9: Ukrike Steffen and Georg Schett: Mechanisms of bone and cartilage
destruction
* 10: Marina Frleta-Gilchrist and Iain B. McInnes: Cytokines and other
mediators
* 3. Clinical presentation
* 11: Annette van der Helm-van Mil: Clinical features of rheumatoid
arthritis
* 12: Karim Raza, Catherine McGrath, Laurette van Boheemen, and Dirkjan
van Schaardenburg: Pre-rheumatoid arthritis
* 13: Katherine MacDonald, Jennifer Hannah, and James Galloway:
Non-articular manifestations of rheumatoid arthritis
* 14: Kimme Hyrich and Sarah Skeoch: Comorbidity in rheumatoid
arthritis
* 4. Disease assessment
* 15: Josef Smolen: Disease activity assessment in rheumatoid arthritis
* 16: Douglas Veale and Ursula Fearon: Synovial biopsies
* 17: Charles Peterfy, Philip Conaghan, and Mikkel Østergaard:
Radiography in rheumatoid arthritis
* 18: Andrew Filer, Maria Antonietta D'Agostino, and Ilfita Sahbudin:
Ultrasound in rheumatoid arthritis
* 19: Charles Peterfy, Philip Conaghan, and Mikkel Østergaard: MRI in
rheumatoid arthritis
* 5. Impact on life
* 20: Kathryn A. Gibson and Theodore Pincus: Patient physical function
in rheumatoid arthritis
* 21: Emma Dures and Neil Basu: Fatigue
* 22: David L. Scott and Allan Wailoo: Health economics
* 23: Suzanne Verstappen, Cheryl Jones, Abdullah Houssien, and James
Galloway: Rheumatoid arthritis and work
* 6. Non-drug treatments
* 24: Lindsay Bearne and Christina Opava: Exercise
* 25: Heidi Siddle and Anthony Redmond: Foot health
* 26: Alison Hammond, Joanne Adams, and Yeliz Prior: Occupational
therapy
* 27: Marieke M.J.H. Voshaar: Self-management: a patient's perspective
* 7. Drug treatments
* 28: Mark D Russell and Nidhi Sofat: Analgesics, Opioids, and NSAIDs
* 29: Johannes W. G. Jacobs, Marlies C. van der Goes, Johannes W. J.
Bijlsma, and José A. P. da Silva: Glucocorticoids
* 30: David L. Scott: Conventional disease modifying drugs
* 31: Peter Taylor and Nehal Narayan: Tumour necrosis factor inhibitors
* 32: Neelam Hassan and Ernest Choy: Interleukin-6 inhibitors
* 33: Yuzaiful Yusof, Edward Vital, and Maya Buch: B-cell therapies
* 34: Vibeke Strand, Jeffrey Kaine, and John Isaacs: Biosimilars
* 35: Meghna Jani, John Isaacs, and Vibeke Strand: Immunogenicity in
response to biologic agents
* 36: Katie Bechman, James Galloway, and Peter Taylor: The use of JAK
inhibitors in the treatment of rheumatoid arthritis
* 37: Ben G.T. Coumbe, Elena Nikiphorou, and Tuulikki Sokka-Isler:
Combination therapy in rheumatoid arthritis
* 38: Jeremy Sokolove: Translation of new therapies: from bench to
bedside
* 39: James Galloway and Mark Yates: Adverse events in clinical studies
in rheumatoid arthritis
* 8. Management and outcomes
* 40: Tom W. J. Huizinga, Annette van der Helm-van Mil, and Andrew
Cope: Prevention of rheumatoid arthritis
* 41: Kenneth F Baker and Arthur G Pratt: Treatment targets and
remission
* 42: David L. Scott: Clinical outcomes
* 43: Anna-Birgitte Aga, Espen A. Haavardsholm, Till Uhlig, and Tore K.
Kvien: Clinical guidelines
* 44: Angela Zink and Anja Strangfeld: European biologics registers
* 45: Jeff Greenberg and Sheetal Patel: Voluntary patient registries
* 1. History, diagnosis, and epidemiology
* 1: David L. Scott: The history of rheumatoid arthritis
* 2: Daniel Aletaha and Helga Radner: Diagnosis
* 3: James Gwinnutt and Deborah Symmons: The descriptive epidemiology
of rheumatoid arthritis
* 4: Lars Klareskog and Lars Alfredsson: Modifiable and other risk
factors for rheumatoid arthritis: a basis for prevention and better
therapy
* 2. Pathogenesis
* 5: Anne Barton: Genetics and epigenetics of rheumatoid arthritis
* 6: Thomas Crowley, Jason Turner, Andrew Filer, Andy Clark, and Chris
Buckley: Dysregulation of synovial fibroblasts in rheumatoid
arthritis
* 7: Tom W. J. Huizinga: Autoantibodies in rheumatoid arthritis
* 8: Soi-Cheng Law, Pascale Wehr, Harriet Purvis, and Ranjeny Thomas:
Dendritic cells and T cells in rheumatoid arthritis
* 9: Ukrike Steffen and Georg Schett: Mechanisms of bone and cartilage
destruction
* 10: Marina Frleta-Gilchrist and Iain B. McInnes: Cytokines and other
mediators
* 3. Clinical presentation
* 11: Annette van der Helm-van Mil: Clinical features of rheumatoid
arthritis
* 12: Karim Raza, Catherine McGrath, Laurette van Boheemen, and Dirkjan
van Schaardenburg: Pre-rheumatoid arthritis
* 13: Katherine MacDonald, Jennifer Hannah, and James Galloway:
Non-articular manifestations of rheumatoid arthritis
* 14: Kimme Hyrich and Sarah Skeoch: Comorbidity in rheumatoid
arthritis
* 4. Disease assessment
* 15: Josef Smolen: Disease activity assessment in rheumatoid arthritis
* 16: Douglas Veale and Ursula Fearon: Synovial biopsies
* 17: Charles Peterfy, Philip Conaghan, and Mikkel Østergaard:
Radiography in rheumatoid arthritis
* 18: Andrew Filer, Maria Antonietta D'Agostino, and Ilfita Sahbudin:
Ultrasound in rheumatoid arthritis
* 19: Charles Peterfy, Philip Conaghan, and Mikkel Østergaard: MRI in
rheumatoid arthritis
* 5. Impact on life
* 20: Kathryn A. Gibson and Theodore Pincus: Patient physical function
in rheumatoid arthritis
* 21: Emma Dures and Neil Basu: Fatigue
* 22: David L. Scott and Allan Wailoo: Health economics
* 23: Suzanne Verstappen, Cheryl Jones, Abdullah Houssien, and James
Galloway: Rheumatoid arthritis and work
* 6. Non-drug treatments
* 24: Lindsay Bearne and Christina Opava: Exercise
* 25: Heidi Siddle and Anthony Redmond: Foot health
* 26: Alison Hammond, Joanne Adams, and Yeliz Prior: Occupational
therapy
* 27: Marieke M.J.H. Voshaar: Self-management: a patient's perspective
* 7. Drug treatments
* 28: Mark D Russell and Nidhi Sofat: Analgesics, Opioids, and NSAIDs
* 29: Johannes W. G. Jacobs, Marlies C. van der Goes, Johannes W. J.
Bijlsma, and José A. P. da Silva: Glucocorticoids
* 30: David L. Scott: Conventional disease modifying drugs
* 31: Peter Taylor and Nehal Narayan: Tumour necrosis factor inhibitors
* 32: Neelam Hassan and Ernest Choy: Interleukin-6 inhibitors
* 33: Yuzaiful Yusof, Edward Vital, and Maya Buch: B-cell therapies
* 34: Vibeke Strand, Jeffrey Kaine, and John Isaacs: Biosimilars
* 35: Meghna Jani, John Isaacs, and Vibeke Strand: Immunogenicity in
response to biologic agents
* 36: Katie Bechman, James Galloway, and Peter Taylor: The use of JAK
inhibitors in the treatment of rheumatoid arthritis
* 37: Ben G.T. Coumbe, Elena Nikiphorou, and Tuulikki Sokka-Isler:
Combination therapy in rheumatoid arthritis
* 38: Jeremy Sokolove: Translation of new therapies: from bench to
bedside
* 39: James Galloway and Mark Yates: Adverse events in clinical studies
in rheumatoid arthritis
* 8. Management and outcomes
* 40: Tom W. J. Huizinga, Annette van der Helm-van Mil, and Andrew
Cope: Prevention of rheumatoid arthritis
* 41: Kenneth F Baker and Arthur G Pratt: Treatment targets and
remission
* 42: David L. Scott: Clinical outcomes
* 43: Anna-Birgitte Aga, Espen A. Haavardsholm, Till Uhlig, and Tore K.
Kvien: Clinical guidelines
* 44: Angela Zink and Anja Strangfeld: European biologics registers
* 45: Jeff Greenberg and Sheetal Patel: Voluntary patient registries
* 1: David L. Scott: The history of rheumatoid arthritis
* 2: Daniel Aletaha and Helga Radner: Diagnosis
* 3: James Gwinnutt and Deborah Symmons: The descriptive epidemiology
of rheumatoid arthritis
* 4: Lars Klareskog and Lars Alfredsson: Modifiable and other risk
factors for rheumatoid arthritis: a basis for prevention and better
therapy
* 2. Pathogenesis
* 5: Anne Barton: Genetics and epigenetics of rheumatoid arthritis
* 6: Thomas Crowley, Jason Turner, Andrew Filer, Andy Clark, and Chris
Buckley: Dysregulation of synovial fibroblasts in rheumatoid
arthritis
* 7: Tom W. J. Huizinga: Autoantibodies in rheumatoid arthritis
* 8: Soi-Cheng Law, Pascale Wehr, Harriet Purvis, and Ranjeny Thomas:
Dendritic cells and T cells in rheumatoid arthritis
* 9: Ukrike Steffen and Georg Schett: Mechanisms of bone and cartilage
destruction
* 10: Marina Frleta-Gilchrist and Iain B. McInnes: Cytokines and other
mediators
* 3. Clinical presentation
* 11: Annette van der Helm-van Mil: Clinical features of rheumatoid
arthritis
* 12: Karim Raza, Catherine McGrath, Laurette van Boheemen, and Dirkjan
van Schaardenburg: Pre-rheumatoid arthritis
* 13: Katherine MacDonald, Jennifer Hannah, and James Galloway:
Non-articular manifestations of rheumatoid arthritis
* 14: Kimme Hyrich and Sarah Skeoch: Comorbidity in rheumatoid
arthritis
* 4. Disease assessment
* 15: Josef Smolen: Disease activity assessment in rheumatoid arthritis
* 16: Douglas Veale and Ursula Fearon: Synovial biopsies
* 17: Charles Peterfy, Philip Conaghan, and Mikkel Østergaard:
Radiography in rheumatoid arthritis
* 18: Andrew Filer, Maria Antonietta D'Agostino, and Ilfita Sahbudin:
Ultrasound in rheumatoid arthritis
* 19: Charles Peterfy, Philip Conaghan, and Mikkel Østergaard: MRI in
rheumatoid arthritis
* 5. Impact on life
* 20: Kathryn A. Gibson and Theodore Pincus: Patient physical function
in rheumatoid arthritis
* 21: Emma Dures and Neil Basu: Fatigue
* 22: David L. Scott and Allan Wailoo: Health economics
* 23: Suzanne Verstappen, Cheryl Jones, Abdullah Houssien, and James
Galloway: Rheumatoid arthritis and work
* 6. Non-drug treatments
* 24: Lindsay Bearne and Christina Opava: Exercise
* 25: Heidi Siddle and Anthony Redmond: Foot health
* 26: Alison Hammond, Joanne Adams, and Yeliz Prior: Occupational
therapy
* 27: Marieke M.J.H. Voshaar: Self-management: a patient's perspective
* 7. Drug treatments
* 28: Mark D Russell and Nidhi Sofat: Analgesics, Opioids, and NSAIDs
* 29: Johannes W. G. Jacobs, Marlies C. van der Goes, Johannes W. J.
Bijlsma, and José A. P. da Silva: Glucocorticoids
* 30: David L. Scott: Conventional disease modifying drugs
* 31: Peter Taylor and Nehal Narayan: Tumour necrosis factor inhibitors
* 32: Neelam Hassan and Ernest Choy: Interleukin-6 inhibitors
* 33: Yuzaiful Yusof, Edward Vital, and Maya Buch: B-cell therapies
* 34: Vibeke Strand, Jeffrey Kaine, and John Isaacs: Biosimilars
* 35: Meghna Jani, John Isaacs, and Vibeke Strand: Immunogenicity in
response to biologic agents
* 36: Katie Bechman, James Galloway, and Peter Taylor: The use of JAK
inhibitors in the treatment of rheumatoid arthritis
* 37: Ben G.T. Coumbe, Elena Nikiphorou, and Tuulikki Sokka-Isler:
Combination therapy in rheumatoid arthritis
* 38: Jeremy Sokolove: Translation of new therapies: from bench to
bedside
* 39: James Galloway and Mark Yates: Adverse events in clinical studies
in rheumatoid arthritis
* 8. Management and outcomes
* 40: Tom W. J. Huizinga, Annette van der Helm-van Mil, and Andrew
Cope: Prevention of rheumatoid arthritis
* 41: Kenneth F Baker and Arthur G Pratt: Treatment targets and
remission
* 42: David L. Scott: Clinical outcomes
* 43: Anna-Birgitte Aga, Espen A. Haavardsholm, Till Uhlig, and Tore K.
Kvien: Clinical guidelines
* 44: Angela Zink and Anja Strangfeld: European biologics registers
* 45: Jeff Greenberg and Sheetal Patel: Voluntary patient registries